Research Article
Determining Risk Factors That Affect Progression in Patients with Nonproliferative Diabetic Retinopathy
Table 4
Summary statistics for variables collected during the follow-up period by year.
| | Visit | DR progressed n (%) | HbA1c mean (±SD) | SBP mean (±SD) | DBP mean (±SD) | DME n (%) | Anti-VEGF treatment for DME n (% DME eyes) | Number of anti-VEGF treatments for DME eyes mean (±SD) |
| | Baseline (N = 230) | — | 9.71 (±2.35) | 135.6 (±18.2) | 76.3 (±11.5) | 39 (17%) | 3 (8%) | — | | Year 1 (N = 157) | 23 (15%) | 9.17 (±1.90) | 135.4 (±13.6) | 75.2 (±8.2) | 49 (31%) | 26 (53%) | 2.9 (±1.5) | | Year 2 (N = 183) | 46 (25%) | 8.88 (±1.98) | 136.6 (±13.1) | 74.6 (±9.2) | 72 (39%) | 34 (47%) | 3.5 (±1.8) | | Year 3 (N = 175) | 43 (25%) | 8.82 (±1.86) | 138.6 (±13.0) | 73.9 (±9.7) | 82 (47%) | 39 (48%) | 2.6 (±1.7) | | Year 4 (N = 168) | 27 (16%) | 8.89 (±1.96) | 138.0 (±13.0) | 73.1 (±9.0) | 75 (45%) | 30 (40%) | 3.2 (±2.0) | | Year 5 (N = 147) | 32 (22%) | 8.97 (±2.08) | 137.2 (±12.2) | 72.9 (±10.5) | 66 (45%) | 22 (33%) | 3.0 (±2.3) | | Year 6 (N = 123) | 19 (15%) | 8.76 (±1.79) | 137.6 (±12.6) | 72.1 (±11.1) | 53 (43%) | 18 (34%) | 3.4 (±2.3) | | Year 7 (N = 91) | 14 (15%) | 8.71 (±1.82) | 137.9 (±12.7) | 72.8 (±11.2) | 51 (56%) | 12 (24%) | 3.4 (±1.9) | | Year 8 (N = 78) | 7 (9%) | 8.71 (±1.91) | 138.4 (±11.2) | 72.1 (±11.9) | 41 (53%) | 10 (24%) | 2.5 (±1.4) | | Year 9 (N = 38) | 4 (11%) | 8.59 (±1.59) | 134.9 (±12.0) | 70.6 (±17.3) | 22 (58%) | 7 (32%) | 2.1 (±1.2) | | Year 10 (N = 10) | 0 (0%) | 8.16 (±0.93) | 135.7 (±5.1) | 73.4 (±7.1) | 7 (70%) | 3 (43%) | 2.0 (±1.0) |
|
|
DR = diabetic retinopathy; SBP = systolic blood pressure; DBP = diastolic blood pressure; DME = diabetic macular edema; anti-VEGF = antivascular endothelial growth factor; SD = standard deviation.
|
